



17.05.2016, Prof. Kirsten Lauber ,

Klinikum der Universität München

Molecular Oncology Department of Radiation Oncology

'Biological approaches to improve the outcome of cancer radiotherapy'

Radiation therapy is one of the crucial treatment options in cancer therapy, beside surgery and chemotherapy. More than 60 % of all cancer patients receive radiotherapy. However, in some cases, patient shows a radioresistance. In this context, Prof. Kirsten Lauber and her workgroup, investigate how to improve the outcome of cancer radiotherapy by combining ionizing therapy with substances that are already used in the clinical routine, or substances whose target are identified by unbiased approached. In her talk, she presented promising data about different projects ongoing in her lab. One of the studies investigates combination of Bevacizumab with radiotherapy in glioblastoma. Other projects explore molecular predictors of Taxane-based radio-chemotherapy and also radiotherapy in association with the DNA damage response inhibitors in pancreatic cancer. The main aim of Prof. Lauber is to use substances which induce radiosensitivity in cancer cells. Indeed, the association of these treatments with radiotherapy seems to be more efficient and increase the overall survival in mice model.

Alizée Steer